The content discusses the role of PARP inhibitors in treating HR-deficient cancers by trapping PARPs on DNA, leading to DNA double-strand breaks. It highlights the importance of PARP1, TIMELESS, and TIPIN in protecting the replisome from transcription-replication conflicts in early S phase. The synthetic lethality of PARP inhibitors with HR deficiency is attributed to the inability to repair DNA damage caused by these conflicts. Inhibiting transcription elongation or depleting PARP1 can impact the efficacy of treatment in HR-deficient settings.
إلى لغة أخرى
من محتوى المصدر
www.nature.com
الرؤى الأساسية المستخلصة من
by Michalis Pet... في www.nature.com 03-20-2024
https://www.nature.com/articles/s41586-024-07217-2استفسارات أعمق